110 related articles for article (PubMed ID: 26175410)
1. Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.
Wei W; Birrer MJ
Cancer Cell; 2015 Jul; 28(1):7-9. PubMed ID: 26175410
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
3. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Otón T; Silva-Fernández L; Andreu JL
N Engl J Med; 2011 Jan; 364(1):83; author reply 84. PubMed ID: 21208114
[No Abstract] [Full Text] [Related]
4. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Okamoto H; Kobayashi A
N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
[No Abstract] [Full Text] [Related]
5. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
6. Healing the Syk through kinase inhibitors.
Rivera J; Colbert RA
N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
[No Abstract] [Full Text] [Related]
7. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
8. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
9. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
10. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
11. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
Boers M
Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
[No Abstract] [Full Text] [Related]
12. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
13. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
14. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
16. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
18. Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?
Gómez-Puerta JA; Bosch X
Nat Rev Rheumatol; 2011 Mar; 7(3):134-6. PubMed ID: 21304505
[TBL] [Abstract][Full Text] [Related]
19. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.
Kuiatse I; Baladandayuthapani V; Lin HY; Thomas SK; Bjorklund CC; Weber DM; Wang M; Shah JJ; Zhang XD; Jones RJ; Ansell SM; Yang G; Treon SP; Orlowski RZ
Clin Cancer Res; 2015 Jun; 21(11):2538-45. PubMed ID: 25748087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]